Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study

Study (n=310 840 propensity score matched adults who started canagliflozin or GLP-1 agonist) reports a small increase in rate of amputation with canagliflozin (18 more amputations per 10 000 people), mostly for adults aged 65 or older with baseline cardiovascular disease.

British Medical Journal